Schizophrenia and the nitric oxide controversy: Do all things fall into place now?

Synapse

Volumn 65, Issue 6, 2011, Pages 545-546

  Bernstein, Hans Gert ^a   Becker, Axel ^a   Keilhoff, Gerburg ^a   Grecksch, Gisela ^a   Bogerts, Bernhard ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; KETAMINE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE;

BRAIN REGION; HIPPOCAMPUS; HUMAN; LETTER; NITRERGIC NERVE; NONHUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA; SYNAPSE;

ANIMALS; FEMALE; HALOPERIDOL; HIPPOCAMPUS; MALE; NITRIC OXIDE;

EID: 79953268071     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20871     Document Type: Letter

References (4)

1. Bernstein HG, Grecksch G, Becker A, Höllt V, Bogerts B. 1999. Cellular changes in rat brain areas associated with neonatal hippocampal damage. Neuroreport 10: 2307-2311.
2. Bernstein HG, Bogerts B, Keilhoff G. 2005. The many faces of nitric oxide in schizophrenia. A review. Schizophr Res 78: 69-86.
3. Keilhoff G, Becker A, Grecksch G, Wolf G, Bernstein HG. 2004. Repeated application of ketamine to rats induces changes in hippocampal expression of parvalbumin, neuronal nitric oxide synthase and cFOS similar to those found in human schizophrenia. Neuroscience 126: 591-598.
4. Negrete-Díaz JV, Baltazar-Gaytán E, Bringas ME, Vazquez-Roque RA, Newton S, Aguilar-Alonso P, León-Chávez BA, Flores G. 2010. Neonatal ventral hippocampus lesion induces increase in NO levels which is attenuated by subchronic haloperidol treatment. Synapse 64: 941-947.